Join our daily newsletter At The Bell to receive exclusive market insights
- Neuren Pharmaceuticals (NEU) has completed manufacturing the its second drug candidate, NNZ-2591
- Pleasingly, this marks the fourth of nine milestones Neuren is hoping to achieve this year
- The drug aims to treat people who suffer from neurological disorders such as Pitt Hopkins syndrome
- Once the company submits the relevant applications to the U.S. Food and Drug Administration, it will conduct phase two trials targeting three disorders
- Additionally, the Neuren made enough of the drug substance for a phase two trial to treat patients with Prader-Willi syndrome
- Neuren’s shares ended the day a slight 1.99 per cent in the green to close at $1.28
Neuren Pharmaceuticals (NEU) has completed manufacturing the drug substance for phase two trials of its second drug candidate, NNZ-2591.
NNZ-2591 has been developed to treat people who suffer from neurological disorders such as Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome.
Essentially, the drug aims to mimic the normal function of the brain and help control and normalise the biological process.
Neuren is preparing to submit investigational new drug applications to the U.S. Food and Drug Administration to carry out trials to treat children with the above mentioned neurological disorders.
“We have successfully developed a proprietary process for large-scale manufacturing with exceptional purity and high yield,” CEO Jon Pilcher said.
“As well as supplying the upcoming trials in Phelan-McDermid, Angelman and Pitt Hopkins, the campaign has produced enough drug substance at no extra cost to supply a phase two trial in Prader-Willi syndrome,” he added.
Significantly, completing the production of the drug substance marks the fourth of nine milestones that Neuren hopes to tick off over the course of 2021.
Neuren’s shares ended the day a slight 1.99 per cent in the green to close at $1.28.
